Lily Qi, Representative for the 15th legislative district in the Maryland House of Delegates. Joins BioTalk to discuss her career, Biotech in Montgomery County, and being a supporter of the BioHealth Capital Region
Listen now on Google https://bit.ly/3sW3iHE, Apple https://apple.co/3yvdkR4, Spotify https://spoti.fi/3yxKRdw, TuneIn https://bit.ly/3zz8gww
Lily Qi, Representative for the 15th legislative district in the Maryland House of Delegates. Joins BioTalk to discuss her career, Biotech in Montgomery County, and being a supporter of the BioHealth Capital Region
Listen now on Google https://bit.ly/3sW3iHE, Apple https://apple.co/3yvdkR4, Spotify https://spoti.fi/3yxKRdw, TuneIn https://bit.ly/3zz8gww
Emergent BioSolutions Inc. is conducting phase clinical 3 trials of its plasma-derived therapy for outpatient treatment of COVID-19, the company announced this week.
The randomized clinical trial will assign participants to receive infusions of either a placebo or the plasma treatment. Emergent is one of two companies providing hyperimmune globulin products for the trial, which plans to enroll 820 patients across the U.S. and abroad.
Automating adjudication of events in cardiovascular trials Clinical trials for cardiovascular (CV) disease are time consuming and expensive to run, often requiring large patient populations to meet the statistical requirements needed to demonstrate efficacy.1 These trials require robust data packages to achieve market approvals and registrations in order to get essential new medicines to patients.
Image: https://www.astrazeneca.com
The U.S. government’s announcement that it is investing $3 billion into research on antiviral medicines for Covid-19 is a step in the right direction and comes at a critical moment in the pandemic — though earlier, of course, would have been better.
But based on my experience with drug development, in particular with antivirals, in both government and the private sector, I know that the process takes longer and is more expensive than anyone ever anticipates. I believe that $3 billion in federal funds is not nearly enough, and that at least $10 billion in clinical research funding is needed to discover and develop the new antiviral medicines that patients desperately need and that physicians have been asking for since the start of the pandemic.
Thank you so much for joining us in this interview series. Before we dive in, our readers would love to learn a bit more about you. Can you tell us a bit about your childhood backstory and how you grew up?
I had an introverted childhood growing up in an orthodox Hindu family with my caring parents, two brothers, and paternal grandparents. My father was a bank officer all his life and has been my major inspiration. He had his master’s in mathematics and was a child prodigy at it. He could do 6-digit multiplication and division faster than I could crunch the numbers in a calculator.
Image: https://medium.com
Avian H7N9 influenza viruses cause sporadic outbreaks of human infections and threaten to cause a major pandemic. The breadth of B cell responses to natural infection and the dominant antigenic sites recognized during first exposure to H7 HA following infection are incompletely understood. Here, we studied the B cell response to H7 HA of two individuals who had recovered from natural H7N9 virus infection. We used competition-binding, hydrogen-deuterium mass spectrometry, and single-particle negative stain electron microscopy to identify the patterns of molecular recognition of the antibody responses to H7 hemagglutinin.
Home to the National Institutes of Health and operations of nearly every leading biopharmaceutical company, Montgomery County, Maryland, has been on the frontlines of coronavirus vaccine research and other life-saving developments. Its thriving life sciences sector is among the diverse industries that had brought steady population growth to the County. Over the past decade, demand for housing and retail services—as well as land prices—had grown dramatically. In response to growing constituent needs, Montgomery County set out to transform its real estate management.
State-of-the-art biomanufacturing-ready office space is coming to Frederick County.
Matan Companies recently broke ground on the new Progress Labs at Riverside I in Frederick. Located in Riverside Research Park, the 215,000 square-foot project is adjacent to the National Cancer Institute’s Frederick National Laboratory and just four miles from Fort Detrick.
This project is a significant addition to Maryland’s biohealth cluster, which is home to numerous leading companies and federal agencies and where office and laboratory space for bio companies remains in high demand.
Image: https://open.maryland.gov
The National Institutes of Health (NIH) Applicant Assistance Program (AAP) is designed to assist small businesses with an interest in preparing and submitting a Small Business Innovation Research or Small Business Technology Transfer (SBIR/STTR) application to any of the following Institutes and Centers:
